走向和远离阿尔茨海默病的途径
1Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, 5600 Nathan Shock Drive, Baltimore, Maryland 21224, USA. mattsonm@grc.nia.nih.gov
Nature
|August 6, 2004
概括
阿尔茨海默病 (AD) 通过破坏神经细胞导致记忆力丧失和认知能力下降. 了解AD中的分子变化可能会导致新的治疗方法来阻止或逆转神经退行.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特点是记忆力丧失和认知能力下降.
- 这种疾病的结果是神经元的功能障碍和死亡,这些神经元对于信息处理至关重要.
- 目前的治疗方法只能提供暂时的症状缓解,缺乏阻止或逆转疾病进展的能力.
研究的目的:
- 总结我们目前对阿尔茨海默氏症病原体的理解.
- 突出需要针对潜在的神经退行过程的新型治疗策略.
- 强调最近细胞和分子研究的进步对开发有效干预措施的潜力.
主要方法:
- 对有关阿尔茨海默氏病的现有文献的审查.
- 对AD中神经退行症背后的细胞和分子机制的分析.
- 综合当前的研究趋势在AD治疗.
主要成果:
- 阿尔茨海默病涉及渐进的神经元功能障碍和死亡,导致严重的认知和人格变化.
- 现有的药物干预措施只能改善暂时的记忆.
- 在了解AD中神经元死亡的分子基础方面取得了重大进展.
结论:
- 迫切需要对阿尔茨海默病采取有效的预防和治疗策略.
- 对阿尔茨海默病细胞和分子变化的持续研究至关重要.
- 了解疾病机制的进展为未来的治疗方法提供了希望,这些治疗方法可以阻止或逆转神经退行.
相关概念视频
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease l: Introduction
29
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29
Alzheimer Disease ll: Pathophysiology
42
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42
Parkinson Disease ll: Pathophysiology
34
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
34
Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35


